HRA Pharma Acquires the Mederma Brand from Merz Pharmaceuticals
June 27, 2019
Laboratoire HRA Pharma SAS has completed the acquisition of the global rights to the Mederma brand (including Mederma, Mederma AG, Eldertonic and Nu‑Iron products) from Merz Pharmaceuticals GmbH; terms were not disclosed. The deal gives HRA Pharma a strong consumer healthcare platform in the United States and supports its strategy to grow its US footprint through organic launches and further targeted acquisitions; Merz said the divestiture sharpens its focus on aesthetics and neurotoxins.
- Buyers
- HRA Pharma
- Targets
- Mederma (brand)
- Sellers
- Merz Pharmaceuticals GmbH
- Industry
- Consumer Products
- Location
- United States
- Transaction Type
- Divestiture
Explore More
Related Acquisitions
-
Eruptr Acquires Medicom Health's HRA Business
December 14, 2021
Healthcare Services
Eruptr Holdings, Inc. has completed the acquisition of the health risk assessment (HRA) business line of Medicom Health, LLC, expanding Eruptr's digital marketing and patient engagement offerings for hospitals and health systems. The deal adds a market-leading HRA product that is complementary to Eruptr's existing HealthAware solution and supports capability expansion at scale; Eruptr is PE-backed by H.I.G. Growth Partners.
-
ESTEVE Acquires HRA Pharma Rare Diseases from Perrigo
May 14, 2025
Pharmaceuticals
Barcelona-based ESTEVE completed the acquisition of HRA Pharma Rare Diseases (the rare-diseases business previously held by Perrigo) in July 2024, in a divestiture transaction announced by Perrigo for up to €275 million. The deal expands ESTEVE's rare-disease portfolio and strengthens its presence in Europe and the United States while supporting the company’s strategic focus on highly specialized therapies.
-
WellSpring Consumer Healthcare Acquires DerMend and Recticare from Ferndale Pharma Group
January 12, 2026
Consumer Products
WellSpring Consumer Healthcare, an Avista Healthcare Partners portfolio company, has acquired the DerMend and Recticare brands from Ferndale Pharma Group. The add-on expands WellSpring’s therapeutic skincare and OTC product portfolio and strengthens its omni-channel retail and e-commerce distribution; financial terms were not disclosed.
-
NovaBay Pharmaceuticals Acquires DERMAdoctor
September 28, 2021
Consumer Products
NovaBay Pharmaceuticals, Inc. has entered into a definitive agreement to acquire DERMAdoctor, LLC for $15.0 million ( $12.0 million cash at closing plus up to $3.0 million in earnouts). The deal brings DERMAdoctor's ~30-product skincare portfolio and its 13-person team (co-founders Audrey and Jeff Kunin to remain) into NovaBay's commercial platform to expand its presence in the U.S. beauty market and capture revenue and operating synergies.
-
Nemera Acquires Insight Product Development
August 8, 2019
Medical Devices
Nemera has acquired Insight Product Development, a Chicago-based healthcare-focused design and innovation consulting firm, and integrated it into Nemera’s newly branded Insight Innovation Center. The acquisition strengthens Nemera’s front-end innovation, human factors and design engineering capabilities and expands its North American development footprint to better serve drug delivery and medical device customers.
-
Essity Acquires Hydrofera to Expand Advanced Wound Care Portfolio
December 29, 2021
Medical Devices
Essity has acquired US-based advanced wound care company Hydrofera for USD 116 million, with a potential additional earnout of up to USD 15 million. Hydrofera, headquartered in Manchester, Connecticut with about 90 employees, brings Hydrofera Blue antibacterial wound dressings and distribution relationships across hospitals, clinics and long-term care—supporting Essity's Medical Solutions capability expansion.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.